Diamyd Medical AB (publ) (DYMDF) Discusses Negative Interim Results From Phase 3 DIAGNODE-3 Trial Transcript

Core Insights - The company is conducting a Phase III study for a disease-modifying therapy aimed at preserving insulin-producing capacity in Type 1 diabetes, which could support potential marketing applications in Europe and the U.S. [1] - The study employs a precision medicine approach, targeting a specific genetic subgroup of Type 1 diabetes patients rather than treating the broader population [2]